Literature DB >> 33711262

Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey.

Lloyd B Mulenga1, Jonas Z Hines2, Sombo Fwoloshi3, Lameck Chirwa4, Mpanji Siwingwa4, Samuel Yingst5, Adam Wolkon5, Danielle T Barradas5, Jennifer Favaloro6, James E Zulu7, Dabwitso Banda7, Kotey I Nikoi4, Davies Kampamba4, Ngawo Banda8, Batista Chilopa8, Brave Hanunka5, Thomas L Stevens5, Aaron Shibemba3, Consity Mwale9, Suilanji Sivile3, Khozya D Zyambo10, Alex Makupe3, Muzala Kapina11, Aggrey Mweemba3, Nyambe Sinyange7, Nathan Kapata12, Paul M Zulu11, Duncan Chanda13, Francis Mupeta14, Chitalu Chilufya15, Victor Mukonka11, Simon Agolory5, Kennedy Malama15.   

Abstract

BACKGROUND: Between March and December, 2020, more than 20 000 laboratory-confirmed cases of SARS-CoV-2 infection were reported in Zambia. However, the number of SARS-CoV-2 infections is likely to be higher than the confirmed case counts because many infected people have mild or no symptoms, and limitations exist with regard to testing capacity and surveillance systems in Zambia. We aimed to estimate SARS-CoV-2 prevalence in six districts of Zambia in July, 2020, using a population-based household survey.
METHODS: Between July 4 and July 27, 2020, we did a cross-sectional cluster-sample survey of households in six districts of Zambia. Within each district, 16 standardised enumeration areas were randomly selected as primary sampling units using probability proportional to size. 20 households from each standardised enumeration area were selected using simple random sampling. All members of selected households were eligible to participate. Consenting participants completed a questionnaire and were tested for SARS-CoV-2 infection using real-time PCR (rtPCR) and anti-SARS-CoV-2 antibodies using ELISA. Prevalence estimates, adjusted for the survey design, were calculated for each diagnostic test separately, and combined. We applied the prevalence estimates to census population projections for each district to derive the estimated number of SARS-CoV-2 infections.
FINDINGS: Overall, 4258 people from 1866 households participated in the study. The median age of participants was 18·2 years (IQR 7·7-31·4) and 50·6% of participants were female. SARS-CoV-2 prevalence for the combined measure was 10·6% (95% CI 7·3-13·9). The rtPCR-positive prevalence was 7·6% (4·7-10·6) and ELISA-positive prevalence was 2·1% (1·1-3·1). An estimated 454 708 SARS-CoV-2 infections (95% CI 312 705-596 713) occurred in the six districts between March and July, 2020, compared with 4917 laboratory-confirmed cases reported in official statistics from the Zambia National Public Health Institute.
INTERPRETATION: The estimated number of SARS-CoV-2 infections was much higher than the number of reported cases in six districts in Zambia. The high rtPCR-positive SARS-CoV-2 prevalence was consistent with observed community transmission during the study period. The low ELISA-positive SARS-CoV-2 prevalence might be associated with mitigation measures instituted after initial cases were reported in March, 2020. Zambia should monitor patterns of SARS-CoV-2 prevalence and promote measures that can reduce transmission. FUNDING: US Centers for Disease Control and Prevention.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33711262     DOI: 10.1016/S2214-109X(21)00053-X

Source DB:  PubMed          Journal:  Lancet Glob Health        ISSN: 2214-109X            Impact factor:   26.763


  44 in total

Review 1.  An exploration of the political, social, economic and cultural factors affecting how different global regions initially reacted to the COVID-19 pandemic.

Authors:  Julian W Tang; Miguela A Caniza; Mike Dinn; Dominic E Dwyer; Jean-Michel Heraud; Lance C Jennings; Jen Kok; Kin On Kwok; Yuguo Li; Tze Ping Loh; Linsey C Marr; Eva Megumi Nara; Nelun Perera; Reiko Saito; Carlos Santillan-Salas; Sheena Sullivan; Matt Warner; Aripuanã Watanabe; Sabeen Khurshid Zaidi
Journal:  Interface Focus       Date:  2022-02-11       Impact factor: 3.906

2.  COVID-19 Vaccine Effectiveness Against Progression to In-Hospital Mortality in Zambia, 2021-2022.

Authors:  Duncan Chanda; Jonas Z Hines; Megumi Itoh; Sombo Fwoloshi; Peter A Minchella; Khozya D Zyambo; Suilanji Sivile; Davies Kampamba; Bob Chirwa; Raphael Chanda; Katongo Mutengo; Mazinga F Kayembe; Webster Chewe; Peter Chipimo; Aggrey Mweemba; Simon Agolory; Lloyd B Mulenga
Journal:  Open Forum Infect Dis       Date:  2022-09-11       Impact factor: 4.423

Review 3.  The Lancet Commission on lessons for the future from the COVID-19 pandemic.

Authors:  Jeffrey D Sachs; Salim S Abdool Karim; Lara Aknin; Joseph Allen; Kirsten Brosbøl; Francesca Colombo; Gabriela Cuevas Barron; María Fernanda Espinosa; Vitor Gaspar; Alejandro Gaviria; Andy Haines; Peter J Hotez; Phoebe Koundouri; Felipe Larraín Bascuñán; Jong-Koo Lee; Muhammad Ali Pate; Gabriela Ramos; K Srinath Reddy; Ismail Serageldin; John Thwaites; Vaira Vike-Freiberga; Chen Wang; Miriam Khamadi Were; Lan Xue; Chandrika Bahadur; Maria Elena Bottazzi; Chris Bullen; George Laryea-Adjei; Yanis Ben Amor; Ozge Karadag; Guillaume Lafortune; Emma Torres; Lauren Barredo; Juliana G E Bartels; Neena Joshi; Margaret Hellard; Uyen Kim Huynh; Shweta Khandelwal; Jeffrey V Lazarus; Susan Michie
Journal:  Lancet       Date:  2022-09-14       Impact factor: 202.731

4.  U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020-February 2022.

Authors:  Amen Ben Hamida; Myrna Charles; Christopher Murrill; Olga Henao; Kathleen Gallagher
Journal:  PLOS Glob Public Health       Date:  2022-08-05

5.  Seroprevalence of SARS-CoV-2 Antibodies in Africa: A Systematic Review and Meta-Analysis.

Authors:  Khalid Hajissa; Md Asiful Islam; Siti Asma Hassan; Abdul Rahman Zaidah; Nabilah Ismail; Zeehaida Mohamed
Journal:  Int J Environ Res Public Health       Date:  2022-06-14       Impact factor: 4.614

6.  Validation of Serological Methods for COVID-19 and Retrospective Screening of Health Employees and Visitors to the São Paulo University Hospital, Brazil.

Authors:  Robert Andreata-Santos; Rafael Rahal Guaragna Machado; Rúbens Prince Dos Santos Alves; Natiely Silva Sales; Camila Pereira Soares; Karine Bitencourt Rodrigues; Mariângela Oliveira Silva; Marianna Teixeira de Pinho Favaro; Mônica Josiane Rodrigues-Jesus; Márcio Massao Yamamoto; Juliana Bannwart de Andrade; Ricardo Ambrósio Fock; Paulo Francisco Ramos Margarido; Cristiane Rodrigues Guzzo Carvalho; Silvia Beatriz Boscardin; Edison Luiz Durigon; Luís C S Ferreira
Journal:  Front Cell Infect Microbiol       Date:  2022-06-02       Impact factor: 6.073

7.  Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201.

Authors:  Kirsten E Wiens; Pinyi Nyimol Mawien; John Rumunu; Damien Slater; Forrest K Jones; Serina Moheed; Andrea Caflisch; Bior K Bior; Iboyi Amanya Jacob; Richard Lino Lako; Argata Guracha Guyo; Olushayo Oluseun Olu; Sylvester Maleghemi; Andrew Baguma; Juma John Hassen; Sheila K Baya; Lul Deng; Justin Lessler; Maya N Demby; Vanessa Sanchez; Rachel Mills; Clare Fraser; Richelle C Charles; Jason B Harris; Andrew S Azman; Joseph F Wamala
Journal:  Emerg Infect Dis       Date:  2021-06       Impact factor: 6.883

8.  A fast extraction-free isothermal LAMP assay for detection of SARS-CoV-2 with potential use in resource-limited settings.

Authors:  Kathleen Gärtner; Harry Meleke; Mercy Kamdolozi; David Chaima; Lyson Samikwa; Mary Paynter; Maggie Nyirenda Nyang'Wa; Elaine Cloutman-Green; Eleni Nastouli; Nigel Klein; Tonney Nyirenda; Chisomo Msefula; Dagmar G Alber
Journal:  Virol J       Date:  2022-05-02       Impact factor: 5.913

9.  SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey.

Authors:  Mohamed Bailor Barrie; Sulaiman Lakoh; J Daniel Kelly; Joseph Sam Kanu; James Squire; Zikan Koroma; Silleh Bah; Osman Sankoh; Abdulai Brima; Rashid Ansumana; Sarah A Goldberg; Smit Chitre; Chidinma Osuagwu; Justin Maeda; Bernard Barekye; Tamuno-Wari Numbere; Mohammed Abdulaziz; Anthony Mounts; Curtis Blanton; Tushar Singh; Mohamed Samai; Mohamed A Vandi; Eugene T Richardson
Journal:  medRxiv       Date:  2021-07-05

10.  Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.

Authors:  Ifedayo M O Adetifa; Sophie Uyoga; John N Gitonga; Daisy Mugo; Mark Otiende; James Nyagwange; Henry K Karanja; James Tuju; Perpetual Wanjiku; Rashid Aman; Mercy Mwangangi; Patrick Amoth; Kadondi Kasera; Wangari Ng'ang'a; Charles Rombo; Christine Yegon; Khamisi Kithi; Elizabeth Odhiambo; Thomas Rotich; Irene Orgut; Sammy Kihara; Christian Bottomley; Eunice W Kagucia; Katherine E Gallagher; Anthony Etyang; Shirine Voller; Teresa Lambe; Daniel Wright; Edwine Barasa; Benjamin Tsofa; Philip Bejon; Lynette I Ochola-Oyier; Ambrose Agweyu; J Anthony G Scott; George M Warimwe
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.